

# *Anopheles gambiae* Immune Responses to Human and Rodent *Plasmodium* Parasite Species

Yuemei Dong<sup>1</sup>, Ruth Aguilar<sup>1</sup>, Zhiyong Xi<sup>1</sup>, Emma Warr<sup>1</sup>, Emmanuel Mongin<sup>2,3</sup>, George Dimopoulos<sup>1\*</sup>

**1** W. Harry Feinstone Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States, **2** Department of Human Genetics and Genome Quebec Innovation Centre, McGill University, Montreal, Quebec, Canada, **3** European Molecular Biology Laboratory, European Bioinformatics Institute, The Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom

**Transmission of malaria is dependent on the successful completion of the *Plasmodium* lifecycle in the *Anopheles* vector. Major obstacles are encountered in the midgut tissue, where most parasites are killed by the mosquito's immune system. In the present study, DNA microarray analyses have been used to compare *Anopheles gambiae* responses to invasion of the midgut epithelium by the ookinete stage of the human pathogen *Plasmodium falciparum* and the rodent experimental model pathogen *P. berghei*. Invasion by *P. berghei* had a more profound impact on the mosquito transcriptome, including a variety of functional gene classes, while *P. falciparum* elicited a broader immune response at the gene transcript level. Ingestion of human malaria-infected blood lacking invasive ookinetes also induced a variety of immune genes, including several anti-*Plasmodium* factors. Twelve selected genes were assessed for effect on infection with both parasite species and bacteria using RNAi gene silencing assays, and seven of these genes were found to influence mosquito resistance to both parasite species. An MD2-like receptor, AgMDL1, and an immunolectin, FBN39, showed specificity in regulating only resistance to *P. falciparum*, while the antimicrobial peptide gambicin and a novel putative short secreted peptide, IRSP5, were more specific for defense against the rodent parasite *P. berghei*. While all the genes that affected *Plasmodium* development also influenced mosquito resistance to bacterial infection, four of the antimicrobial genes had no effect on *Plasmodium* development. Our study shows that the impact of *P. falciparum* and *P. berghei* infection on *A. gambiae* biology at the gene transcript level is quite diverse, and the defense against the two *Plasmodium* species is mediated by antimicrobial factors with both universal and *Plasmodium*-species specific activities. Furthermore, our data indicate that the mosquito is capable of sensing infected blood constituents in the absence of invading ookinetes, thereby inducing anti-*Plasmodium* immune responses.**

Citation: Dong Y, Aguilar R, Xi Z, Warr E, Mongin E, et al. (2006) *Anopheles gambiae* immune responses to human and rodent *Plasmodium* parasite species. PLoS Pathog 2(6): e52. DOI: 10.1371/journal.ppat.0020052

## Introduction

The transmission of the malarial parasite *Plasmodium* by the vector mosquito *Anopheles gambiae* is enabled by hematophagy, which is essential for egg production. Within 24 h after ingestion of infected blood, the *Plasmodium* gametocytes are fertilized and develop into motile ookinetes, which invade and traverse the mosquito midgut epithelium to reach its basal side, where they develop into oocysts. *Plasmodium* encounters several obstacles at each of its developmental stages and spatial transitions within the mosquito. One of the major barriers is the midgut epithelium, within which *Plasmodium* is attacked by the mosquito's immune system. These defense reactions involve a variety of immune components that reduce the parasite population by several-fold and have mainly been described at the stage of ookinete invasion and beyond [1].

Survival of ookinetes in the midgut epithelium has been shown to depend on the action of agonists and antagonists. Recent studies have identified two infection-inducible putative pattern recognition receptors, Tep1 and LRIM1, that can mediate killing of ookinetes in the midgut epithelium; in contrast, two c-type lectins, CTL4 and CTLMA2, can protect the ookinetes from destruction [2]. Other known factors with activity against the midgut stages of *Plasmodium* include nitric oxide, the antimicrobial peptides gambicin and cecropin, and an apolipoprotein precursor RFABG [3–7]. Recent studies

have linked the *A. gambiae* NF-kappaB-like transcription factor REL2 and adaptor protein IMD to the defense against *P. berghei* and thereby established a role for the putative IMD pathway in anti-*Plasmodium* defense [8]. *Plasmodium* infection will also affect a variety of other biological processes in addition to those linked to the immune response [7].

Activation of immune gene transcription has also been documented prior to ookinete invasion, suggesting that other constituents of malaria-infected blood are sensed by the immune surveillance system and can thereby elicit immune

**Editor:** Alan Sher, National Institutes of Health, United States of America

**Received:** September 13, 2005; **Accepted:** April 24, 2006; **Published:** June 9, 2006

**DOI:** 10.1371/journal.ppat.0020052

**Copyright:** © 2006 Dong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Abbreviations:** AGBP, bacteria recognition family; AgMDL, *Anopheles gambiae* MD2-like protein; CTL, C-type lectin family; CTRP, circumsporozoite- and TRAP-related protein; dsRNA, double-strand RNA; FBN, fibrinogen domain immunolectin family; GALE, gal-lectin family; GGBP, Gram-negative bacteria binding protein family; KS, Kolmogorov-Smirnov; LRRD, leucine-rich repeat domain protein family; ML, MD2-like; PBS, phosphate-buffered saline; PGRP, peptidoglycan recognition protein family; Tep, thioester-containing protein family; wt, wild-type

\* To whom correspondence should be addressed. E-mail: gdimopou@jhsph.edu

## Synopsis

The malarial parasite *Plasmodium* has to traverse the gut wall of the *Anopheles* mosquito in order to complete its lifecycle and to be transmitted between hosts. At the midgut stage of infection, the mosquito activates immune responses to eliminate most invading parasites. The features of these immune responses are not very well understood and have mainly been examined using the rodent parasite model *P. berghei*. Here the authors investigated the relationship between the *Anopheles gambiae* responses against the human pathogen *P. falciparum*, the rodent parasite *P. berghei*, and bacterial infections, at both the gene expression and functional levels. The mosquito responses against these pathogens were quite diverse, and the defense against the two malaria parasite species involved both common and species-specific components. Malaria-infected blood was sufficient to activate anti-*Plasmodium* immune responses, even in the absence of midgut invasion. Through this mechanism, the mosquito can initiate its defense against *Plasmodium* prior to invasion of the gut. Mosquito genes that could negatively influence *Plasmodium* development were also capable of regulating the resistance to bacterial infection, but several of the antibacterial genes had no effect on *Plasmodium*; thus, the mosquito apparently utilizes its antibacterial defense systems against the malaria parasite.

responses [9]. The ingested malaria-infected blood differs from noninfected blood in a number of ways, including the presence of blood-stage and gametocyte-stage *Plasmodium* and their metabolites, and of vertebrate infection-responsive molecules, as well as higher free-radical concentrations [10,11]. These biochemical and cellular factors can be expected to influence a variety of biological processes in the mosquito, including the activation of immune responses [3]. Midgut invasion by ookinetes is accompanied by apoptosis of the invaded epithelial cells, which are expelled into the lumen [12].

Most studies addressing *A. gambiae* responses to *Plasmodium* infection have utilized the rodent *Plasmodium berghei* model system, which is more amenable to experimental manipulation than is the human parasite *P. falciparum*. However, *A. gambiae* is not the natural vector of *P. berghei*, for which it is significantly more permissive than for *P. falciparum*: *P. berghei* frequently produces more than 300 oocysts on the midgut epithelium, while *P. falciparum* rarely produces more than two to five oocysts, either under laboratory conditions or in nature [13,14]. At present, the dependence of these infection levels on the mosquito's immune responses or other factors is not known. At the cellular level, the ookinete invasion route and midgut epithelial response appear to be similar for the two parasite species, but the process may proceed more rapidly for *P. falciparum* at some stages because of its  $\sim 3^\circ\text{C}$  higher temperature of infection [15,16]. The mosquito's immune system is most likely predominantly devoted to combating the bacterial and fungal pathogens present in its external environment and intestinal flora, and it is unclear whether defense mechanisms have evolved that are specific for *Plasmodium* [17,18].

We have used an experimental design involving wild-type (wt) and transgenic mutant parasite strains of both *P. falciparum* and *P. berghei* species to analyze and compare *A. gambiae* responses, at the global transcript level, to the invading ookinetes of both human and rodent parasite species and to human malaria-infected blood lacking invasive ookinetes. A similar strategy has been used previously [7] to

analyze midgut transcriptomic responses to *P. berghei* ookinete invasion; however, this previous study was more broadly focused on midgut responses relating to a variety of biological processes rather than the specific immune responses to the parasite. We have furthermore compared the anti-*Plasmodium* immune responses with those acting against bacteria with RNAi gene-silencing assays. Our analysis provides insight into the species specificity of the immune defense against *Plasmodium* and its relationship to the mosquito's antibacterial defense system.


## Results

### Responses to Invasion of the Midgut Epithelium by *P. falciparum* and *P. berghei* Ookinetes

Ookinete-stage *Plasmodium* invades the mosquito midgut epithelium over a 10-h period beginning about 20 h after ingestion of infected blood. The peak of *P. berghei* ( $21^\circ\text{C}$ ) and *P. falciparum* ( $24^\circ\text{C}$ ) ookinete invasion occurs at 24–26 h after ingestion [17,19]. To assess the impact of ookinete midgut invasion on the mosquito transcriptome, we compared gene expression in the gut and carcass tissues of mosquitoes that had fed on a wt *Plasmodium*-infected blood and those that had fed on blood infected with an invasion-incapable circumsporozoite- and TRAP-related protein (CTRP) knockout ( $\text{CTRP}^-$ ) *Plasmodium* mutants. The experimental strategy used to assay the mosquito responses to ookinete invasion and infected blood is presented in Figure 1A. Identical assays with wt *Plasmodium* and CTRP knockout mutants were conducted with *P. falciparum* and *P. berghei*, allowing comparison of the mosquito responses to midgut invasion by ookinetes of the two parasite species. The entire predicted *A. gambiae* transcriptome was screened in these assays using a 60-mer oligonucleotide microarray (Agilent Technologies, Palo Alto, California, United States). The gene regulation threshold cutoff was determined to be 1.74-fold, which corresponds to 0.8 in  $\log_2$  scale, according to [20].

*P. falciparum* ookinete invasion triggered the regulation of 471 genes in the midgut and carcass tissues, corresponding to  $\sim 3.4\%$  of the mosquito transcriptome; *P. berghei* ookinete invasion elicited changes in the expression of 1,102 genes, corresponding to 8.1% of the mosquito transcriptome. The mosquito midgut and carcass responses to *P. falciparum* and *P. berghei* ookinete invasion were remarkably divergent, with only limited overlap in gene expression (Figure 1B–D); for example, the overlap in transcriptional responses to the two parasite species in the midgut involved only 16 induced and five repressed genes. Midgut invasion by the *P. falciparum* ookinetes elicited less profound gene regulation than *P. berghei*. Specifically, *P. falciparum* induced 265 genes and repressed 65 genes in the midgut, while *P. berghei* invasion produced alterations in more than three times as many genes, inducing 623 and repressing 292 (Figure 1B–D).

*P. falciparum* induced more putative immune genes in the mosquito midgut than did *P. berghei* (48 versus 35; Figure 1C and 1D). It is possible that a proportion of the *P. berghei* induced genes is implicated in as-yet-unknown defense mechanisms and has therefore not been assigned to the immunity class. In general, fewer genes were induced or repressed in the carcass by ookinete invasion of the midgut (141 for *P. falciparum* versus 187 for *P. berghei*; Figure 1B–D). Quantitative RT-PCR assays of the expression patterns of 15



**Figure 1.** Experimental Design and Global Gene Expression Patterns at the Different Conditions of Infection

(A) Model outlining the experimental design for assessing responses to the invading ookinetes (indicated as *P.f.* ookinete [*P.f.* o.] and *P.b.* ookinete [*P.b.* o.] in (B) and (C) by comparing transcription between mosquitoes fed on blood infected with a wt *Plasmodium* strain and those fed on blood infected with the invasion-incapable mutant *Plasmodium* strain CTRP<sup>-</sup>. Responses to infected blood (indicated as *P.f.* blood in [B] and [C]) in the absence of ookinete invasion were assessed by comparing gene expression between mosquitoes fed on blood infected with the *P. falciparum* invasion-incapable mutant and mosquitoes fed on non-infected (no *Plasmodium*) blood.

(B) Gene regulation in midgut and carcass tissues triggered by *P. falciparum* ookinete invasion (*P.f.* ookinete), *P. berghei* ookinete invasion (*P.b.* ookinete), and *P. falciparum* strain CTRP<sup>-</sup>-infected blood lacking invasive ookinetes (*P.f.* blood). Colored arrows indicate genes that are up- or down-regulated in the various unique and overlapping sections. (C) Proportions and numbers of genes belonging to distinct functional classes which were up- or down-regulated by the various stimuli in the gut and carcass tissues. DIV: diverse; R/T/T: replication, transcription, translation; MET: metabolism; TRP: transport; CY/ST: cytoskeletal, structural; PR/DI: proteolysis, digestion; MIT: mitochondrial; RE/ST: oxidoreductive, stress-related; APO: apoptosis; P/A: putative immunity and apoptosis. Gene functions were predicted based on Gene Ontology data and manual sequence homology searches.

(D) Same as in (C), but also including genes of diverse functions (DIV) and unknown functions (UKN).

DOI: 10.1371/journal.ppat.0020052.g001

control genes, under several experimental conditions, validated microarray assays (Figure S1; Table S4; Protocol S1).

### Responses to Malaria-Infected Blood in the Absence of Midgut Invasion

The impact on the mosquito midgut and carcass transcriptomes of *P. falciparum*-infected blood that lacked invasive ookinetes was investigated by comparing gene expression between mosquitoes that had fed on blood infected with the CTRP knockout mutant *P. falciparum* strain (incapable of ookinete invasion; used as experimental sample) and mosquitoes fed on non-*Plasmodium*-infected blood (used as a reference sample) at 24 h after ingestion, when ookinete invasion of the midgut normally takes place (Figure 1A). The mosquitoes were clearly capable of sensing and discriminating between infected blood and non-infected blood.

Ingestion of CTRP knockout-infected blood elicited changes in the expression of as many as 1,896 genes in the midgut and carcass tissues, corresponding to approximately 14% of the *A. gambiae* transcriptome (Figure 1B–1D; Tables S1 and S2). The magnitude of the gene regulation in the midgut in response to *P. falciparum* CTRP knockout mutant-infected blood was comparable to that induced by *P. berghei* ookinete invasion (844 versus 915 genes). Six times as many genes (1,052) were affected in the carcass tissues as were regulated by *P. berghei* ookinete invasion (187). The 487 induced and 357 repressed genes in the midgut tissue represented a variety of functional classes, including 51 putative immune genes.

### Molecular Immune Responses

Invasion of the midgut epithelium by *P. falciparum* and *P. berghei* ookinetes as well as infected blood containing non-invasive ookinetes induced putative immune-related genes. Genes that showed significant up- or down-regulation (at least 1.74-fold) in at least one experiment were grouped into clusters according to the specificity of their regulation for the midgut tissue and/or carcass. We divided these 157 transcripts into seven groups based on their expression patterns and tissue specificity (Table 1).



**Table 1.** Grouping of Putative Immune Genes into Seven Distinct Groups, According to their Regulatory Significance in the Midgut and Carcass Tissue

Group	Functional Class	Name	P.f. Gut	P.b. Gut	P.f.CTRP Gut	P.f. Carc	P.b. Carc	P.f.CTRP Carc	E.c.	S.a.	RNAi P.f.	RNAi P.b.	RNAi E.c.	RNAi S.a.
Group 1	PRR	E20083:AgMDL1	1.7	-1.0	-0.6	0.6	0.2	0.0	1.5	0.3	(-)*	NS	(-)*	(-)*
		E16963:AgMDL2	1.4	-1.5	-0.5					1.1				
		E16857:TEP1	2.1	-0.3	0.3	0.6	0.2	1.5	2.3	-0.7	(-)*	(-)*	E*	E*
		E21216:TEP4	0.9	0.4	0.5	0.1	0.1	1.9	1.7	1.6		NS	(-)*	(-)*
		E16853:TEP6	1.1	-0.2	-0.2	0.1	0.5	0.5	0.2	-0.6				
		E13026:TEP12	1.3	-0.3	-0.2	0.6	0.2	0.5	0.3	-0.7				
		E19727:TEP14	1.4	0.1	-0.1	0.2	0.1	0.5	1.8	-0.4				
		E19522:TEP15	1.4	-0.3	-0.9	0.0	-0.5	1.0	1.8	1.0				
		E21282:TEP16	1.8	0.1	-0.5	0.3	0.0	1.8	1.8	-0.5				
		E29396:FBN51	1.6		0.9	0.7	-0.8	0.6	-0.4	-1.2				
		E11252:FBN8	1.9	-0.4	0.1	0.4	0.8	0.1	-0.1	-0.1	(-)*	(-)*	(-)*	(-)*
		E11248:FBN9	1.6	0.0	0.8	0.2	0.0	1.7	2.5	0.7	(-)*	(-)*	(-)*	(-)*
		E21822:LRRD7	3.0	-1.0	1.1				2.2	-1.1	(-)*	(-)*	(-)*	(-)*
		E19113:LRRD4	1.7	-0.2	0.7	-0.1	-0.3	2.2	0.9	0.5				
		E15066:LRRD5	2.2	-0.7	0.1				-0.6	0.0				
		E14959:LRRD8	1.3	-0.6	-0.3				0.9	-0.6				
		E19115:LRRD9	1.7		0.4	-0.2	-0.2	2.3	1.5	-0.2				
		E06959:AGBP1	1.8	-1.2	-0.8					0.7		NS	NS	(-)*
	E12234:CTLGA3	1.5		0.2	0.2	0.4	0.1	2.2	-0.8					
	SPC	E20941:SP PPO ACTIVATE	1.8			0.2	-0.7	-1.1	2.3	-0.3				
		E13584:SP 14D2 CLIPB1	1.5	0.1	0.2	0.1	-0.8	0.7	2.1	-0.2				
		E23726:SP CLIPB4	0.9	0.9	0.5	0.1	-0.5	2.0	0.8	0.4				
		E12706:SP CLIPA9	1.4	0.7	0.5	0.3	-0.4	1.6	1.8	-0.4				
		E12642:SP CLIPB13	1.1	-0.4	-0.5	0.0	-0.3	0.3	1.7					
		E15815:SP CLIPB15	1.2	-0.3	0.1	0.3	0.3	0.9	1.8	-0.2				
		E11374:SP SNAKE-LIKE	1.6	-1.0	1.1				0.0	0.2				
		E20158:SP CLIP1	1.8	-0.7	-0.3	0.3	0.4	1.3	1.9	-0.2	(-)*	(-)*	(-)*	(-)*
		E08842:SP CLIP2	1.0	0.0	0.6	-0.2	-0.4	1.7	0.9	1.0				
		E21812:SERPIN2	1.2	-0.2	0.2	0.4	-0.3	0.9	2.1					
	M	E18532:PACIFASTIN	1.4	0.2	0.4	0.0	0.3	2.7	1.8	0.3				
		E02437:PPO3	1.1	-1.0	-0.1	0.0	0.5	-0.2	-0.8	-0.5				
		E14433:DCE LIKE1	0.9	0.3	-0.2	0.2	-0.4	0.3	0.8	-0.2				
		E20450:DCCE2	2.8		1.9	0.2	-0.3	1.6	1.8	-0.1				
	AMP	E21028:IRSP1	3.1	-1.5						-0.8	(-)*	(-)*	(-)*	(-)*
		E19220:IRSP2	2.3	-0.4	-2.2	1.3	0.4	-2.1	0.6	1.1	NS	NS	(-)*	(-)*
		E09630:IRSP3	2.3	0.0										
E19451:IRSP5		2.9	-1.6					2.7	0.6	NS	(-)*	(-)*	NS	
DIV	E17888:LYSOZYME1	2.9		0.8				-0.2	-1.8					
	E18395:LYSOZYME4	1.3	-0.5	-0.1				0.0	0.7					
	E10802:CUT4	0.9		0.1	0.0	-0.4	-1.1							
	E13822:CUT5	1.2	1.0	-0.4				-1.0	-0.9					
	E26190:CUT9	0.8	-0.3					0.1	0.4					
	E21949:TRANSFERRIN	1.4	-0.1	0.4	-0.4	-0.8	3.3	1.5	0.4					
Group 2	PRR	E28106:APOD	1.4	-0.8	-0.1	0.5	-0.4	0.5	1.9	-0.4	(-)*	(-)*	(-)*	(-)*
		E08856:F SPONDIN	2.7	-1.0	-0.2	-0.2	-0.8	1.1	2.4	-0.4				
		E20281:FBN18	0.2	1.1	-0.2	0.3	0.9	-0.6	-0.7	-0.4				
		E08964:FBNa2	0.2	1.1	-0.6	-0.2	0.9	0.9	0.3	-0.4				
		E20316:FBNB33	0.0	1.0	0.5	0.0	-0.1	0.5	0.5	-0.2				
		E11478:FBN-LIPASE	-0.4	1.0	0.2	0.2	0.3	0.4	0.0	-0.4				
		E15624:GALE5a	0.2	1.1	-0.1	0.3	0.2	-0.4	0.2	0.1				
		E28711:GALE5b	-0.2	1.6	-0.2	-0.1	0.3	-0.2	-0.6	0.6				
		E17035:GNBPP3	-0.2	0.9	0.3	-0.1	0.8	-2.1	-1.0	-0.6				
		E16221:GNBPP4	-0.2	1.0	0.0				-0.3	-0.1				
Group 2	PRR	E07504:LRRD1	-0.1	1.6	-0.1				-0.5	-0.3				
		E17816:LRRD2	-0.1	0.8	0.4	0.2	0.3	1.0		-0.5				
		E14905:LRRD10a	0.0	1.3	-0.2	0.0	0.3	-0.8	0.1	-1.2				
		E15569:LRRD10b	0.0	1.0	0.1				-0.4	-0.2				
		E11337:LRRD11	-0.2	1.0	-0.6				-1.0	-0.7				
		E11311:LRRD14	-0.2	1.1	-0.2	0.0	0.3	-0.5	1.4	0.0				
		E19036:LRRD17		0.9	-0.1				0.2	0.0				
		E15763:LRRD20	-0.1	1.2	0.3				1.3	-1.4				
		E29002:PGRPLC 1-3	0.1	1.2	-0.3				0.4	-0.3				
		E12978:PGRP AMIDASE	0.0	0.8	1.4	-0.1	0.0	-0.5	0.1	0.2		NS	NS	(-)*
		E12979:PGRPS3	0.0	1.4	1.0	0.2	-0.1	1.7	-0.3	-1.3				
		E22427:SRB1 SR BI	0.2	1.4	-0.5				-0.3	-0.9				
E12288:SCRBQ2	0.4	1.2	0.6	0.1	0.3	0.6	-0.2	-0.6						

Table 1. Continued

Group	Functional Class	Name	<i>P.f.</i> Gut	<i>P.b.</i> Gut	<i>P.f.</i> CTRP Gut	<i>P.f.</i> Carc	<i>P.b.</i> Carc	<i>P.f.</i> CTRP Carc	<i>E.c.</i>	<i>S.a.</i>	RNAi <i>P.f.</i>	RNAi <i>P.b.</i>	RNAi <i>E.c.</i>	RNAi <i>S.a.</i>
	SPC	E15833:SERPIN1B	-0.1	0.8	-0.2				0.8	-0.5				
		E10507:SERPIN5	0.0	0.8	0.4	-0.4	-0.7		0.6	-0.1				
		E19065:SP INHIBITOR KAZ1	-0.2	1.1	0.0				-0.2	0.1				
	M	E16955:PPO1	-0.2	1.1	-0.6				-0.9	0.4				
	A	E18439:LYSOZYME2	-0.4	2.1	1.1				0.9	0.1				
	DIV	E13340:CUT11	0.2	1.1	-0.2	0.2	0.0	-0.4	-0.7	-0.5				
		E23320:CUT12	-0.1	1.6	-0.2	0.5	0.5	-0.6	-0.8	-0.8				
		E10057:CUT8	-0.4	1.1	0.4				-0.6	-1.1				
Group 3	PRR	E28194:A2M LIKE1	-0.5	0.3	1.2	0.1	-0.2	-0.5	-0.2	-0.2				
		E11296:FBNA4			0.9	0.8	-0.7	-0.1	-0.4	-0.2				
		E21318:FBNA24	-0.6	0.2	1.5				-0.1	-0.3				
		E13811:FBNA36	0.2	0.4	1.0									
		E22867:FBNA50	-0.2		1.6	0.4	-0.2	1.9	0.7	-1.1				
		E21166:CTL4	0.0	-0.2	1.6	-0.1	-0.7	1.4	2.4	0.2			E*	
		E16937:GNBP LIKE			1.0				0.0	0.3				
		E13948:PGRPLB	-0.3	0.3	1.5	-0.1	0.1	0.2	-0.9	-1.2				
		E21511:LRRD, FN- TYPE III	-0.4	0.6	0.8				-0.3	-0.8				
		E23264:LRRD13	0.0	-0.4	1.0	0.2	0.0	0.0	-0.2	-1.2				
		E21533:LRRD15	-0.4		0.9				0.3	-0.9				
		E04718:LRRD18	-0.3	0.3	0.9				-0.5	-0.7				
		E10921:LRRD19	0.4	0.4	1.2	-0.1	0.5	0.5	1.2	1.3				
		E27057:DSCAM	0.1	-0.1	0.8				1.2	0.3				
	SPC	E18122:SP CLIPB14	0.5		1.4				2.3	0.6				
		E21259:SP CLIPC7	0.3	-0.4	1.8	-0.1	0.8	0.6	1.8	0.9				
		E13861:SP5	0.0		1.2				-0.2	0.2				
		E15886:SP SNAKE-LIKE2	0.1	0.8	2.4				0.7	0.5				
	I	E20964:IKKB	-1.0		0.9				1.9	0.0				
	A	E13255:GAMBICIN		0.1	3.2				-0.7	NS	(-)*	NS	(-)*	
		E25070:LYSOZYME3	-0.2	-0.3	1.1				1.4	-1.0				
	M	E22659:DCE LIKE2	0.1	0.7	0.9				1.4	-0.7				
		E29284:DCCE1	0.1	0.4	1.2	0.4	-0.6	0.9	1.5	-0.8				
	P	E10572:CED			1.6				-1.0	0.8				
	D	E27865:CUT10	0.5	0.4	0.8				-0.5	-0.1				
Group 4	P	E29579:FBNA5			0.5	0.8	0.6	0.3	0.1	-1.1				
		E17928:CTLMA4				0.9	-0.1	0.6	-0.7	1.2				
	M	E22058:HECY1				1.1	-0.2		-0.4	0.0		NS	NS	(-)*
		E22055:HECY2				0.9	-0.3	-0.2	-0.3	-0.6				
Group 5	PRR	E18121:TEP9				0.1	1.2	0.3	-0.2	-0.7				
		E02335:FBNA24				0.6	1.3		-0.6					
		E26094:FBNA15				0.3	1.3		-0.3	0.0				
		E12652:SCRIB7				0.7	1.1		0.1	-0.1				
	A	E20428:NOS					1.2	-1.1	0.4	0.6				
Group 6	PRR	E14456:FBNA (EGF)				0.1	0.6	1.3	1.0	0.2				
		E22610:FBNA6	0.5	0.7	0.3	0.4	-0.5	1.0	1.9	-0.7				
		E08288:FBNA5	0.0	0.2	0.4	0.1	0.8	0.9	-0.3	0.7				
		E13041:LRRD11	0.7		0.2	0.2	-0.1	1.6	0.4	-0.6			E*	
		E12396:LRRD				-0.7	-0.8	1.5	-0.1	-0.6				
		E14508:LRRD19	0.5	0.0	0.3	0.0	0.3	0.9	1.8	0.0				
		E17320:PGRPS1	-0.2	-0.2	0.3	-0.4	-0.9	1.0	0.1	-0.2				
	SPC	E17184:SP CLIPD7				0.0	0.2	0.9	0.2	-0.2				
		E10201:SP INHIBITOR KAZ3			-0.6	-1.2	-1.0	1.8		0.6				
		E13422:SP SNAKE-LIKE3				0.3	-0.4	1.5	0.0	-0.2				
		E07878:SP CLIP3				0.0	-0.3	1.4	-0.5	-0.1				
		E27174:SP CLIP4	0.5	-0.1	0.2	0.0	-0.1	1.8	2.1	-0.3				
		E26523:SP CLIP5				0.5		2.1	-0.7	-1.5				
		E21796:SP22D	0.3	0.1	0.3	-0.1	0.0	1.3	2.1	-0.2				
		E07723:SRPN3	0.5		-0.1	0.1	-0.1	1.6	1.0	0.3				
		E04662:SRPN4	0.0	0.8	0.3	-0.1	0.0	1.0	1.5	-0.4				
	AMP	E11995:CECROPIN 3	-0.3		0.3	-1.2	-0.5	1.7		-0.7				
		E15621:DEFENSIN 1			-0.2	-0.5	-0.4	2.6	-0.2	1.2				
		E26058:NOS				-0.2	-0.2	1.0	-0.3	-0.4				
		E25363:NOS				0.0	0.6	0.8	-0.6	0.0				
	DIV	E22116:FERRITIN	0.0		0.3	-0.1	-0.2	1.0	2.2	1.2				
		E14280:CUT14				-0.1	0.9	1.0	0.0	-0.3				
		E10987:A-2-M RECEPTOR ASSOC				0.4	0.0	1.9	0.0	0.0				

Table 1. Continued

Group	Functional Class	Name	<i>P.f.</i> Gut	<i>P.b.</i> Gut	<i>P.f.</i> CTRP Gut	<i>P.f.</i> Carc	<i>P.b.</i> Carc	<i>P.f.</i> CTRP Carc	<i>E.c.</i>	<i>S.a.</i>	RNAi <i>P.f.</i>	RNAi <i>P.b.</i>	RNAi <i>E.c.</i>	RNAi <i>S.a.</i>
Group 7 (1)	PRR	E17003:AgMDL3	0.5		-1.3				1.5	-0.2				
		E16922:AgMDL4	-1.6		0.2	-0.1	0.7	0.5	-0.5	0.1				
		E28973:AgMDL5	0.1	-1.0	0.4				-0.7	-0.3				
		E16849:TEP7	-0.6	-1.0	0.1				-0.6	3.0				
		E20938:CTLMA6	-0.2	-0.4	-1.0	0.1	-0.3		-0.5	0.3				
		E17694:GNBPB1	0.1		-1.1	0.1	0.2	1.3	0.1	0.1		(-)*	(-)*	NS
		E05042:LRRD12	-0.9	0.4	0.2	0.2	-0.7	0.5	-0.2	-0.3				
		E14342:LRRD16	-0.8		0.4				-0.6	-0.7				
		E14345:LRRD12	0.7	0.2	-0.9	-0.4	0.1	0.5	-0.4					
		E10496:SP CLIPB12	0.3	-1.7	0.4				-0.5	0.4				
		E28244:SP INHIBITOR KAZ2	0.4	-1.4	0.6				-1.1	0.1				
		E24778:SP SNAKE-LIKE1			-1.0				0.7	-0.7				
		E16631:APOLIPOPORIN III	0.1	-2.6	0.7	-1.5	-0.3	-1.4						
		Group 7 (2)	PRR	E19994:F SPONDIN	0.0	-0.4	-0.9				0.3	0.9		
E12780:CUT3	0.1			-0.9	0.2				2.7	-0.1				
E18232:CUT6	0.3			0.1	-1.0	0.2	0.5	-1.2	-0.1	-0.7				
E22552:CUT7	0.3			-0.9	0.1	-0.1	-0.3	0.9	2.7	-0.2				
E18120:TEP8								-1.2	-0.3					
E11308:FBN35						-0.6	-1.1		-0.6	0.0				
E21372:SCRB7						0.2	-0.5	-1.5	-0.4	-0.1				
SP	E21354:SP CLIP1				0.2	-0.9	0.2	2.3	-0.1					
	E25996:DEFENSIN 2				0.4	-0.3	-1.4	-0.9	-0.5					
A	E11541:CUT13	0.0	0.4	0.4	0.0	0.2	-0.9	-0.4	-0.4					
	E26827:CUT15				-1.2	-0.1		-0.8	-0.7					
DIV	E18253:CUT16						-0.8	-0.2	0.0					
	E13093:SAPOSIN B				0.0	0.5	-2.0	0.0	-0.3					

Gene IDs have been abbreviated by deleting the "NSANGT000000" part that follows the "E." Numbers indicate Log<sub>2</sub>-transformed -fold differences in regulation between compared samples. Groups 1, 2, and 3 consist of genes with significant induction in the midgut tissue upon *P. falciparum* ookinete invasion (*P.f.o.Gut*), *P. berghei* ookinete invasion (*P.b.o.Gut*), and at 24 h after feeding on infected blood lacking invasive ookinetes (*P.f.b.Gut*), respectively. Groups 4, 5, and 6 consist of genes with specific induction in the carcass tissue upon *P. falciparum* ookinete invasion (*P.f.o.Carc*), *P. berghei* ookinete invasion (*P.b.o.Carc*), and at 24 h after feeding on infected blood lacking invasive ookinetes (*P.f.b.Carc*), respectively. Group 7 consists of genes with diverse and mostly repressed regulation under the various conditions and in different tissues. Expression profiles of genes in *E. coli*- and *S. aureus*-challenged mosquitoes, as compared to PBS-injected mosquitoes, are designated *E.c.* and *S.a.*, respectively. Genes within each group have been ordered according to their putative functional class (second column). PRR(P), pattern recognition receptors; SPC(S), serine proteases cascades; MEL(M), melanization; AMP(A), proteins mediating antimicrobial activity; DIV(D), diversified and novel; IMM(I), immune signaling; PHA(P), phagocytosis. Effects of genes, subjected to RNAi gene silencing, on *Plasmodium* development and mosquito survival after bacterial challenge are shown on the right and are indicated as RNAi *P.f.*, RNAi *P.b.*, RNAi *E.c.* and RNAi *S.a.* (-)\*: the repressive effect of genes on parasite and bacterial survival, with the asterisks indicating statistically significance at the 95% confidence level. NS, nonsignificant difference; E\*, significant difference effect based on other published studies.  
DOI: 10.1371/journal.ppat.0020052.t001


Groups 1, 2, and 3 consisted of 45 genes that were induced in the midgut by *P. falciparum* ookinete invasion, 29 genes induced by *P. berghei* ookinete invasion, and 25 genes induced by ingested infected blood lacking invasive ookinetes (the CTRP mutant), respectively. While *P. falciparum* ookinete invasion induced almost twice as many immune genes as did the other two infection conditions, the distribution of functional classes was quite similar among the three groups. Almost half of the genes in each group encoded putative pattern recognition receptors that belong to the MD2-like protein family (AgMDL), the fibrinogen domain immunolec- tin family (FBN), the thioester-containing protein family (Tep), the Gram-negative bacteria binding protein family (GNBP), the peptidoglycan recognition protein family (PGRP), the C-type lectin family (CTL), gal-lectin family (GALE), the scavenger receptor family, the leucine-rich repeat domain protein family (LRRD), and the bacteria recognition family (AGBP) [18,21–29]. We suggest that some of these proteins are required for the recognition of *Plasmodium* and subsequent activation of defense reactions. Other transcripts in groups 1–3 encoded immunity-related serine proteases and serine protease inhibitors that are most likely involved in immune signal amplification cascades. Several transcripts encoding enzymes involved in melanization reactions were induced in

the midgut. Finally, lysozymes and the mosquito-specific antimicrobial peptide gambicin (E13255) were induced.

Groups 4, 5, and 6 consisted of immune genes that were induced in the carcass tissues, and group 7 consisted of a variety of immune genes that were mostly repressed under the various experimental conditions.

The proportion of genes induced in invaded cells may be larger than that seen for the entire midgut tissue, because a relatively small number of cells is invaded by ookinetes; we therefore suspect that we might have missed genes that are highly expressed in invaded cells but are diluted out by the rest of the midgut. Hemocytes that are attached to the midgut wall but difficult to separate by dissection have been shown to express Tepl, LRIM1, and other effectors that act against *Plasmodium* in the midgut [2,30]. Some of the gene activation that we detected in infected midgut samples is therefore likely to be derived from hemocytes. Preliminary studies have shown that as many as 30 of the 157 putative immune genes listed in Table 1 are highly expressed in hemocytes (Strand and Dimopoulos, unpublished data). Many of the immune genes identified here have also been found to be induced in the midguts of *A. gambiae* refractory L3–5 and susceptible G3 and 4A-RR strain mosquitoes upon *P. berghei* infection [7,17,31].

Our analyses identified several novel infection-responsive



**Figure 2.** Effects of Gene Silencing of 11 Selected Putative Immune Genes on *P. falciparum* and *P. berghei* Infection

The gene silencing efficiency values (KD %) are displayed in Table S6. The frequency distribution of oocysts pooled from three independent assays is displayed, with bars indicating the percentile of mosquitoes with the corresponding oocyst number in the range indicated on the x-axis. Equal numbers of midguts from all three experiments in each dataset were pooled. Bars with asterisks indicate the statistically significant differences at the 95% confidence level, based on the *p* value from two independent probability tests, the KS and Mann-Whitney tests (Tables S5 and S6). n: total midguts assayed; MI: mean intensity of infection (oocysts number); S.E.: standard error of mean intensity; *p* value: from Mann-Whitney test. DOI: 10.1371/journal.ppat.0020052.g002

genes that we suggest are components of the mosquito's immune system; these are discussed in detail in the Supporting Information (Protocol S1). Data concerning other biological processes in the mosquito that are affected by ookinete invasion of the midgut and ingestion of malaria-infected blood are detailed in the Supporting Information (Protocol S1).

### Determinants of Mosquito Resistance to Infection

We assume that the mosquito's immune response is largely regulated at the level of mRNA abundance [2,7,17,32]. Based on this assumption, we predict that many of the infection-stimulated immunity-related genes are necessary to defend against *Plasmodium*. We took an RNAi-based reverse genetic approach to test the role these induced genes played in fighting a *Plasmodium* infection. Transcripts of selected genes were targeted with double-strand RNAs (dsRNAs) prior to experimental infection with the pathogens to assess the potential effects of the transcript depletion on the infection phenotype. Nineteen genes were selected on the basis of their

expression patterns and putative functions in innate immunity, as predicted by their sequences. The efficiency of RNAi-mediated transcript depletion was verified by quantitative real-time RT-PCR (Table S6 in Results S1). These 19 genes encode putative pattern recognition receptors (AgMDL1, TEP1, TEP4, FBN8, FBN9, FBN39 [E21380]), LRRD7, AGPB1, PGRP-AMIDASE, GNBPB1; the serine protease SPCLIP1; the antimicrobial peptide gambicin; the hemocyanin HECY1, the apolipoprotein APOD; the kininogen KIN1; and four short secreted peptides, IRSP1, IRSP2, IRSP3, and IRSP5. Two genes were tested but did not display any significant effects (*KIN1* [E14131] and *IRSP3* [E09630]) (unpublished data). *Tep1* was used as a positive control as silencing of *Tep1* in a susceptible G3 *A. gambiae* strain results in an up to 7-fold increase in *P. berghei* infection [30]. All genes were used in challenge experiments with *P. berghei* while only a subset of genes were tested with *P. falciparum* because of the difficulty of performing these experiments. Detailed information on the genes selected for gene silencing assays is presented in the Supporting Information (Protocol S1).

### Anti-Plasmodium Defense Activities

Silencing of 11 of the transcripts (*Tep1*, *AgMDL1*, *FBN8*, *FBN9*, *FBN39*, *SPCLIP1*, *APOD*, *IRSP1*, *IRSP5*, *LRRD7*, *gambicin*) resulted in increased *Plasmodium* levels, in both the present work and previous studies [22,23,30,33–36] (Dimopoulos, unpublished data; Figures 2 and 3; Tables S5 and S6). The effects of gene silencing on the susceptibility to *Plasmodium* infection were evident in the differences between the gene-silenced and green fluorescent protein (GFP) dsRNA-treated control mosquitoes in terms of the proportion of mosquitoes exhibiting a very low number of oocysts and the proportion exhibiting exceptionally high oocyst numbers (Figures 2 and 3). Although most of these anti-*Plasmodium* factors were induced in the midgut tissue, several were also induced in carcass tissues (Table 1).


Seven genes that strongly influenced both *P. falciparum* and *P. berghei* development, *Tep1*, *APOD*, *FBN8*, *FBN9*, *SPCLIP1*, *IRSP1*, and *LRRD7*, were all induced in the mosquito midgut upon *P. falciparum* ookinete invasion but not in *P. berghei*-infected mosquitoes (Figure 2 and Table 1). Silencing of *AgMDL1* and *FBN39* showed a more pronounced effect on *P. falciparum* development, while silencing of the gene encoding the antimicrobial peptide *gambicin* and an infection-responsive secreted peptide gene *IRSP5* had a specific effect on the resistance to *P. berghei* infection.

Though *P. falciparum* appeared to elicit a stronger immune response at the gene transcript level than *P. berghei*, knock-down of most of the genes that were specifically induced by *P. falciparum* ookinete invasion surprisingly also affected *P. berghei* levels.

### Relationships between Anti-Plasmodium and Antibacterial Immune Responses

To assess the relationships between the transcriptional immune responses to *Plasmodium* and other immune challenges, we compared the gene expression in mosquitoes injected with *Escherichia coli* and *Staphylococcus aureus* to *Plasmodium*-infected mosquitoes. Of the 132 genes that were induced by *Plasmodium* ookinete invasion or infected blood, 49 were also induced by *E. coli* challenge, and 12 genes were induced by *S. aureus* challenge. The *E. coli* infection-responsive





**Figure 3.** Comparison of Anti-*Plasmodium* and Antibacterial Activities for 16 Selected Immune Genes

(A) Effect of gene silencing on *P. berghei* development, as described in Table S6. For ease of comparison, only the mosquito portions with the highest *P. berghei* oocyst numbers (>200) are presented. The effect of gene silencing on bacterial infection is presented as the mosquito survival at d 6 after challenge with *E. coli* and *S. aureus*. After 6 d, the survival rates stabilized and did not change significantly until age-related mortality ensued. The baseline survival rate was set to that of the challenged GFP dsRNA-treated control mosquitoes (~70%). Standard error bars with asterisks indicate the results of two-way analysis of variance, with  $p < 0.05$  considered statistically significant. The gene names are numbered for ease of comparison.

(B) Mosquito survival rates for each silenced gene after challenge with *E. coli* and *S. aureus*. The numbers in parenthesis correspond to the numbers in (A). Open squares, dsGFP control-treated mosquitoes challenged with *E. coli*; solid squares, dsGFP control-treated mosquitoes challenged with *E. coli*; open triangles, gene-silenced mosquitoes challenged with *E. coli*; and solid triangles, gene-silenced mosquitoes challenged with *S. aureus*. Standard error bars from three replicate experiments are included for each time point.

DOI: 10.1371/journal.ppat.0020052.g003

transcripts included eight genes (*Tep1*, *FBN9*, *FBN39*, *LRRD7*, *CTL4*, *SPCLIP1*, *IRSP5*, and *APOD*) that can influence *Plasmodium* development and resistance to bacterial challenge (Table 1 and Figures 2 and 3; presented below). The overlap between *Plasmodium*- and bacteria-elicited immune gene regulation supports the hypothesis that the mosquito is utilizing some of the same immune pathways and mechanisms for defense against these two classes of pathogen.

All 19 genes that were tested for their effect on *P. berghei* development through RNAi-mediated depletion were also able to influence mosquito resistance to bacterial challenge and can therefore be considered as components of the antibacterial defense. The anti-*Plasmodium* factors *Tep1*, gambicin, and NOS have been shown in previous studies to mediate anti-*Plasmodium* and antibacterial defenses [3,4,30]. Five genes encoding *IRSP2*, *Tep4*, *PGRP-AMIDASE*, *AGBP1*, and *HECY1* were specific for antibacterial defense and had no significant effect on the *Plasmodium* infection (Table 1 and Figure 3). Three genes that had effects on mosquito survival upon *S. aureus* challenge, *PGRP-AMIDASE*, *AGBP1*, and *HECY1*, had no significant effects on survival after *E. coli* challenge or infection by *Plasmodium*, whereas two genes, *IRSP5* and *GNBPB1*, were more specific for *E. coli* and *P. berghei*. Only one gene, *gambicin*, could influence resistance to both *P. berghei* and *S. aureus*.


## Discussion

Both *Plasmodium* ookinete invasion and other factors in infected blood serve as triggers of the immune and other responses by the *Anopheles* mosquito. The diverse midgut responses to *P. falciparum* and *P. berghei* infection can be attributed to differences in infection level and in the biology of interaction between the two parasite species and the mosquito [13,37]. Achieving comparable infection levels for the human and rodent parasites in *A. gambiae*, through artificial manipulation of infections, would be difficult and not appropriate for the scope of this study, which addresses the relevance of analyses with a laboratory experimental model. The unnaturally high infection levels in *P. berghei* are useful for the experimental analysis of gene expression patterns that may be undetectable at the low infection levels of *P. falciparum*. An example of this phenomenon is the induction of cytoskeletal genes in this and other studies upon *P. berghei* infection, that have been shown to act as both agonists and antagonists of *Plasmodium* [7,38]. The smaller number of induced putative immune genes upon *P. berghei* infection may indicate that the mosquito's immune surveillance system is more capable of sensing *P. falciparum*, or *P. berghei* may in some way suppress the mosquito's immune response, and that could partly explain the significantly higher infection levels of the rodent parasite in *A. gambiae*.

While the midgut is the primary site of response to the invading ookinetes, the observed changes in gene expression in the carcass tissues, at a time point when the ookinetes are in the midgut epithelium, most likely reflect intertissue signaling from the midgut epithelium to hemocytes and fat body cells, possibly through cytokine-like molecules. Alternatively, parasite-derived molecules that diffuse into the hemolymph may affect mosquito biological processes in the carcass tissues of the mosquito [24].

The broader effect of infected blood on gene regulation, as





**Figure 4.** AgMDL Gene Family

(A) *A. gambiae* MD2-like genes encode proteins ranging from 130 to 162 amino acids and include signal peptides and an ML lipid recognition domain. Alignment of AgMDL1 with the human homologues MD1, MD2, and Npc2, the mite allergen Der-P2, and the *Bombyx mori* promotor protein (BmPP). Two conserved cysteines, Cys95 and Cys105, that are essential for binding to TLR4 are indicated with asterisks.

(B) Phylogenetic tree of MD2-like proteins from *A. gambiae*, *D. melanogaster*, *B. mori*, and humans. 1:1 orthologs and ortholog groups are highlighted with filled circles. Ag, *Anopheles gambiae*; Dm, *D. melanogaster*. The accession numbers for these genes are listed in Table S7.

DOI: 10.1371/journal.ppat.0020052.g004

compared to ookinete invasion of the midgut, can be attributed to the exposure of all the midgut cells to the infected blood components, while only a subset of cells are invaded by the ookinetes, and indicates the extensive qualitative differences between infected and noninfected blood [10,11]. The capacity to mount an immune response to infected blood, in the absence of ookinete invasion, is likely beneficial in controlling *Plasmodium* infection. This strategy would allow for enrichment of anti-*Plasmodium* factors prior to epithelial invasion. *P. falciparum* glycosylphosphatidylinositols in malaria-infected blood have been shown to act as potent elicitors of immune responses [3,11]. It is also possible that the immune response acts against parasite stages in the midgut lumen prior to invasion. For example, the antimicrobial peptide gene *Gambicin*, which is induced by infected blood in the absence of invasion, has been shown to be highly

expressed in the cardia tissue of the anterior midgut, which is not invaded by *Plasmodium* [4] (Dimopoulos lab, unpublished data). From the cardia, gambicin and other effectors may be blended into the blood meal, where they can limit bacterial growth and attack *Plasmodium* in the midgut lumen.

A recent study by Vlachou and coworkers utilized an expressed sequence tag (EST)-based cDNA microarray comprising approximately 8,000 *A. gambiae* genes to assay midgut gene expression responses to *P. berghei* ookinete invasion [7]. Surprisingly, of the 914 *P. berghei* regulated genes identified in the present study and the 346 regulated genes with accession numbers from the previous study, only 25 genes showed similar regulation in the two studies. These differences can presumably be attributed to the differences in the two experimental systems: we utilized different *A. gambiae* and *P. berghei* strains, and a different type of microarray [2]. Even small differences in rearing and infection conditions could also have affected the responses [7,31]. A previous study has also documented significant differences in transcriptional infection responses between different *A. gambiae* lab strains upon challenge with the same pathogens [31]. *A. gambiae* most likely possesses a variety of anti-*Plasmodium* defense mechanisms, and different strains may differ in their usage of these defenses. For instance, one genetically selected *A. gambiae* strain melanotically encapsulates the invading ookinetes, while another selected strain lyses the ookinetes in the midgut epithelium [39,40].

The high proportion of tested genes that had an effect on *Plasmodium* and bacterial infection in this study can be explained by the targeted selection of putative immune genes with a bias towards *P. falciparum* infection-induced transcripts. RNAi gene-silencing assays in *A. gambiae* are based on the direct injection of gene-specific dsRNAs into the hemolymph, which is in direct contact with the fatbody, midgut, hemocytes, and other tissues [41]. The genes we examined are expressed in different tissues and even in different cell types within the same tissues [42]. Consequently, the gene knockdown phenotypes may to some extent also reflect the efficacy of dsRNA uptake and gene silencing of different tissues and cell types in addition to specific gene functions. Several anti-*Plasmodium* genes were expressed in carcass tissues and hemocytes (Strand and Dimopoulos, unpublished data) (Table 1) [2,30]. These factors are likely to be present in the hemolymph, from which they are able to attack the midgut-stage *Plasmodia* on the basal side of the midgut or even within the epithelium by diffusion through the basal labyrinth, which is a channel system extending into the cells [43]. The extensive overlap between gene effects on *P. falciparum* and on *P. berghei* development suggest that the mosquito's defense mechanisms are quite universal for different *Plasmodium* species, although species-specific defense mechanisms also exist.

Silencing of putative anti-*Plasmodium* factors resulted in an increase in *P. falciparum* levels of up to 6-fold; in terms of mean oocyst numbers, this increased level is significantly lower than the infection level of *P. berghei* in non-gene-silenced mosquitoes (Figure 2; Tables S5 and S6). The lower infection level of the human parasite species is therefore attributable to nonimmunity related factors or, alternatively but less likely, to immune factors that were not identified or tested in the present study. It is not yet clear how many of the different anti-*Plasmodium* factors function together in the

same mechanism or pathway, and which may be acting independently. Some of the tested genes may participate in anti-*Plasmodium* defense but not be essential because their function is redundant with that of other immune genes. The infection phenotype of such genes after RNAi knockdown will therefore not differ from that in untreated mosquitoes. Genes with differential effects on infection with different pathogens, such as *gambicin* and *AgMDLI*, could reasonably be expected to act in different defense mechanisms. Future analyses will address the relations and hierarchies of these anti-*Plasmodium* factors in the fight against malaria. Of particular interest is the anti-*P. falciparum*-specific activity of the novel mosquito immune factor *AgMDLI*, which may act as an immune pathway activator similarly to its vertebrate homologue (Figure 4 and Protocol S1) [21,28].

The genes displaying anti-*Plasmodium* activity also influenced the mosquito's resistance to bacterial infection, while several genes with an effect on resistance to bacterial infection did not influence *Plasmodium* development. These findings suggest the mosquito is mainly employing its antimicrobial defense system in the fight against malaria. Although certain immune gene allele frequencies have been correlated with *Plasmodium* exposure in the field, there is little reason to believe that the mosquito would have undergone major adaptations to malaria and evolved highly specific anti-*Plasmodium* defense mechanisms [44,45]. In nature, bacteria and fungi are most likely the major pathogens to which the mosquitoes are continuously exposed. In contrast, exposure to *Plasmodium* is seasonal and usually very low-level, rarely exceeding 25% of the infected mosquitoes in a given population [46]. A recent study has linked the *A. gambiae* anti-*Plasmodium* defense to the REL2F factor, which also mediates activation of the defense against *S. aureus* [8]. Up-regulation of the antibacterial-specific genes *IRSP2*, *Tep4*, *PGRP-AMIDASE*, *AGBP1*, and *HECY1* after *Plasmodium* infection may be attributed to concomitant microbial infections of the midgut epithelium; it is very likely that the ookinete invasion of the epithelium facilitates exposure to bacteria and bacterial components such as lipopolysaccharide and peptidoglycan (Table 1). Through this mode of gene induction, the bacteria may participate in boosting the mosquito's anti-*Plasmodium* defense. Previous studies have shown that antibiotic-treated mosquitoes, with significantly reduced microbial midgut flora, express lower levels of immune genes and are more susceptible to *Plasmodium* infection [19,47]. Conversely, mosquitoes that have been challenged with bacteria are more resistant to *Plasmodium* infection [48].

This study suggests that *P. berghei* is a useful malaria model for studying anti-*Plasmodium* gene function but may be less relevant as a model for studying transcriptional immune responses to ookinete invasion of the midgut epithelium. A comprehensive understanding of the interactions between *Anopheles* and *Plasmodium* can lead to the development of new strategies for controlling malaria, based on the mosquito's own defense against the parasite [49].

## Materials and Methods

**Mosquito rearing and infection assays.** *A. gambiae* Keele strain mosquitoes were maintained on sugar solution at 27 °C and 70% humidity with a 12-h light/dark cycle according to standard rearing procedures [50]. For microarray assays, the carcasses and midguts

from approximately 40 mosquitoes were dissected on ice 24 h after ingestion of blood infected with the wt Anka 2.34 or CTRP<sup>-</sup> *P. berghei* strain, or the wt NF54 or CTRP<sup>-</sup> *P. falciparum* strain, or noninfected human blood. *P. falciparum* gametocyte cultures were prepared as previously described, and mosquitoes were fed on cultures through a membrane feeder at 27 °C and then maintained at 24 °C [51]. *P. berghei* infections were done at 21 °C as previously described [7]. Mosquito midguts were dissected at 7–8 d after feeding and stained with 0.2% mercurochrome. Oocyst numbers per midgut were determined using a light-contrast microscope (Olympus, Tokyo, Japan). *P. berghei* infections with gene-silenced (RNAi) mosquitoes were performed with a transgenic GFP *P. berghei* strain and infection phenotypes were determined as previously described [7]. For preparation of bacterially challenged samples for microarray analyses, 4-d-old female mosquitoes were first injected with approximately 20,000 heat-inactivated *E. coli* or *S. aureus* and approximately 20 whole mosquitoes were collected 4 h after challenge [52]. For bacterial challenge of gene-silenced (RNAi) mosquitoes, *E. coli* and *S. aureus* were cultured in LB broth overnight, then washed three times with phosphate-buffered saline (PBS) before being resuspended in PBS. Approximately 27,000 live *E. coli* or 55,000 *S. aureus* in a 50- $\mu$ l PBS suspension were injected into the mosquito hemolymph 4 d after the dsRNA injections. RNA was extracted from dissected tissues or whole mosquitoes by using the RNeasy kit (Qiagen, Valencia, California, United States). Quantification of RNA was performed using a Biophotometer (Eppendorf, Hamburg, Germany) spectrophotometer, and quality assessment was determined by RNA Nano LabChip analysis on an Agilent Bioanalyzer 2100.

**Probe sequence design and microarray construction.** The release 2a *A. gambiae* sequences were retrieved from Ensembl ([http://www.ensembl.org/Anopheles\\_gambiae](http://www.ensembl.org/Anopheles_gambiae)). These sequences were predicted using a combination of ab initio, EST, and protein similarity-based methods [53–55]. The transcripts were annotated with the Ensembl utility (<http://www.ensembl.org/ensmart>) [56,57]. Oligonucleotides (60 mer) for the 14,180 predicted *A. gambiae* transcripts that corresponded to 13,118 genes were designed using the Oligo Picky software according to the software developer's instructions [58]. Oligonucleotide sequences were designed to be complementary to regions within 1 kb of the 3' untranslated region of transcripts and had a minimal sequence identity overlap with nontarget transcript sequences. Microarrays were constructed through in situ synthesis of oligonucleotides on glass slides by Agilent Technologies.

**Microarray analysis.** Fluorochrome-labeled cRNA probes were synthesized from 2–3  $\mu$ g of RNA using the Agilent Technologies low-input linear amplification RNA labeling kit according to the manufacturer's instructions. Probe quantity was determined with a Biophotometer spectrophotometer, and 16-h hybridizations were performed with the Agilent Technologies in situ hybridization kit according to the manufacturer's instructions. After washes, the prescribed microarrays were instantaneously dried with pressurized air. Microarrays were scanned with an Axon GenePix 4200AL scanner using a 10  $\mu$ m pixel size (Axon Instruments, Union City, California, United States). Laser power was set to 100%, and the photomultiplier tube voltage was adjusted to maximize effective dynamic range and minimize pixel saturation. The spot size, location, and quality were determined using GenePix software Pro 6.0 algorithms, and potential misidentifications of spot locations and quality were corrected manually. Scan images were analyzed, and Cy5 and Cy3 signal and ratio values were obtained using Genepix software. The minimum signal intensity was set to 200 fluorescent units, and the signal-to-background ratio cutoff was set to 2.0 for both Cy5 and Cy3 channels. Three or four biological replicates were performed for each experimental set. The background-subtracted median fluorescent values for good spots (no bad, missing, absent, or not-found flags) were normalized according to a LOWESS normalization method, and Cy5/Cy3 ratios from replicate assays were subjected to *t* tests at a significance level of  $p \leq 0.05$  using TIGR MIDAS and MeV software [59]. For genes with significant *p* values in one experimental set, the expression values from other experimental sets were included when the direction of regulation in all the replicate assays was the same and within a regulation range of  $\leq 0.5$ -fold. Expression data from all replicate assays were averaged with the GEPAS microarray preprocessing software prior to logarithm (base 2) transformation [60]. Self-self hybridizations were used to determine a cutoff value for the significance of gene regulation of 0.8 in log<sub>2</sub> scale, which corresponds to 1.74-fold regulation according to previously established methodology [20]. The false discovery rate was therefore 0.027% (three standard deviations). Microarray-assayed gene expression of 15 genes was further validated with quantitative RT-PCR and showed a high degree of correlation (Pearson correlation coefficient  $r = 0.86$ ; best-fit



linear-regression  $R^2 = 0.75$ ; and the slope of the regression line  $m = 0.996$  for 15 tested genes (Figure S1).

**Real-time quantitative PCR.** RNA samples were treated with Turbo DNase (Ambion, Austin, Texas, United States) and reverse-transcribed using Superscript III (Invitrogen, Carlsbad, California, United States) with random hexamers. Real-time quantification was performed using the QuantiTect SYBR Green PCR Kit (Qiagen) and ABI Detection System ABI Prism 7000 (Applied Biosystems, Foster City, California, United States). All PCR reactions were performed in triplicate. Specificity of the PCR reactions was assessed by analysis of melting curves for each data point. The ribosomal protein S7 gene was used for normalization of cDNA templates. Primer sequences are listed in Table S3.

**RNAi gene-silencing assays.** Sense and antisense RNAs were synthesized from PCR-amplified gene fragments using the T7 Megascript kit (Ambion). The sequences of the primers are listed in Table S3. About 69 nl of dsRNAs (3  $\mu\text{g}/\mu\text{l}$ ) in water was introduced into the thorax of cold-anesthetized 4-d-old female mosquitoes using a nano-injector (Nanoject; Drummond Scientific, Broomall, Pennsylvania, United States) with a glass capillary needle according to established methodology [41]. For gene-silencing assays, 80 4-d-old female mosquitoes were injected, in parallel, with GFP dsRNA as a control group or with target gene-specific dsRNA for the experimental group. Gene silencing was verified 3 to 4 d after dsRNA injection by real-time quantitative RT-PCR, done in triplicate, with the *A. gambiae* ribosomal S7 gene as the internal control for normalization (Table S6). The primers for silencing verification are listed in Table S3. For *Plasmodium* infection assays, 3–4 d after dsRNA injection, at least 50 control (GFP dsRNA-injected) and 50 experimental (gene dsRNA-injected) mosquitoes were fed on the same *P. berghei*-GFP strain-infected mouse or the same NF54 *P. falciparum* culture; 24 h later, the unfed mosquitoes were removed [7]. Mosquito midguts were dissected at 7–8 d after feeding and stained with 0.2% mercurochrome. Oocyst numbers per midgut were determined using a light-contrast microscope (Olympus). Infection phenotypes of the transgenic GFP *P. berghei*-infected mosquitoes were determined as previously described [7]. The mean number of oocysts per midgut was calculated for each tested gene and for GFP dsRNA-injected control mosquitoes. The results for equal numbers of midguts from all three independent biological replicates were pooled. Because of the lower *P. falciparum* infection levels, the Kolmogorov-Smirnov (KS) test was used to check the shape of the oocyst levels' distribution. When the KS test indicated a nonnormal distribution, the rank of sum (Mann-Whitney) test was used to determine the statistical significance (Tables S5 and S6). For bacteria infection assays, 3–4 d after dsRNA injection, at least 50 of each control and experimental mosquitoes were injected with the same *E. coli* or *S. aureus* cultures. Dead mosquitoes were counted and removed daily for 7 d after bacterial challenge. Two-way analysis of variance was used to assess the significance of the gene-silencing effect on mosquito survival after challenge, with  $p < 0.05$  deemed statistically significant. The RNAi gene-silencing assays were done as blinded tests with coded dsRNA samples. The effects on gene silencing are displayed in Table S6 as percentile of knockdown efficiency.

**Phylogenetic analysis.** Full-length or partial predicted sequences of MD2 homologues were aligned using the Clustal X program (<ftp://ftp-igbmc.u-strasbg.fr/pub/ClustalX>), and cladograms were constructed by neighbor-joining analysis and displayed through Treeview (<http://darwin.zoology.gla.ac.uk/~rpage/treeview/download.html>). AgMDL sequences were retrieved from Ensembl [53], and *D. melanogaster* MD2-like proteins (DmML) were retrieved from Flybase (<http://flybase.bio.indiana.edu>). DmMLs were named according to [21]. Genes were only considered as 1:1 orthologues if the relevant bootstrap values were higher than 800 (1,000 iterations).

## Supporting Information

**Figure S1.** Validation of Microarray-Assayed Gene Expression with Real-Time Quantitative RT-PCR

The mean values for the expression data (log<sub>2</sub> ratio) for 15 genes from three midgut assays (*Pf.* ookinete, *Pb.* ookinete, *Pf.* blood) obtained by microarray analysis were plotted against the corresponding mean expression values obtained with real-time RT-PCR from two biological replicates of each experiment. The Pearson correlation coefficient ( $p = 0.86$ ), the best-fit linear-regression analysis ( $R^2 = 0.75$ ), and the slope of the regression line ( $m = 0.996$ ) demonstrated a high degree of correlation of the magnitude of regulation between the two assays. The individual values for all these genes are presented in Table S4.

Found at DOI: 10.1371/journal.ppat.0020052.sg001 (87 KB DOC).

**Protocol S1.** Additional Information on Novel Immune Genes, Transcript Responses to *Plasmodium* Infection, and the Genes Selected for RNAi Screening

Found at DOI: 10.1371/journal.ppat.0020052.sd001 (414 KB DOC).

**Table S1.** Log<sub>2</sub>-Transformed Expression Ratios of *Anopheles gambiae* Genes Showing >1.74-Fold Regulation (0.8 in log<sub>2</sub>) under at Least One Experimental Condition in the Midgut

Expression values of the following microarray assays are presented. Pf GUT, Pf wt gut/Pf CTRP<sup>-</sup> gut; Pb GUT, Pb wt gut/Pb CTRP<sup>-</sup> gut; Pf CTRP, Pf CTRP<sup>-</sup> gut/blood-fed gut; Pf CARC, Pf wt carcass/Pf CTRP<sup>-</sup> carcass; Pb CARC, Pb wt carcass/Pb CTRP<sup>-</sup> carcass; Pf CTRPCARC, Pf CTRP<sup>-</sup> carcass/blood-fed carcass.

Found at DOI: 10.1371/journal.ppat.0020052.st001 (266 KB XLS).

**Table S2.** Log<sub>2</sub>-Transformed Expression Ratios of *Anopheles gambiae* Genes Showing >1.74-Fold Regulation (0.8 in log<sub>2</sub>) under at Least One Experimental Condition in Carcass Tissues

Expression values of the following microarray assays are presented. Pf GUT, Pf wt gut/Pf CTRP<sup>-</sup> gut; Pb GUT, Pb wt gut/Pb CTRP<sup>-</sup> gut; Pf CTRP, Pf CTRP<sup>-</sup> gut/blood-fed gut; Pf CARC, Pf wt carcass/Pf CTRP<sup>-</sup> carcass; Pb CARC, Pb wt carcass/Pb CTRP<sup>-</sup> carcass; Pf CTRPCARC, Pf CTRP<sup>-</sup> carcass/blood-fed carcass.

Found at DOI: 10.1371/journal.ppat.0020052.st002 (189 KB XLS).

**Table S3.** Primers Used to Produce PCR Amplicons for dsRNA Synthesis, Real-Time QRT-PCR for Microarray Validation, and Verification of Gene Silencing

Underlined letters indicated the T7 promoter sequence. The same pair of forward and reverse primers was used for both dsRNA synthesis and QRT-PCR validation of microarray expression data. For the RT-PCR verification of gene silencing, the different veriF primers and reverse primers were used.

Found at DOI: 10.1371/journal.ppat.0020052.st003 (80 KB DOC).

**Table S4.** Correlation of Microarray Expression Data with Real-Time QRT-PCR

Comparison of the expression data from real-time quantitative RT-PCR (QRT) and DNA microarrays (Arrays) for 15 genes. For QRT-PCR, data were obtained from two biological and three technical replicates. The mean value for the regulation and standard error of the mean (SE) for the reactions were obtained from both QRT-PCR and array data. Pearson correlation (P) indicated the consistency between the two methods. N/A indicates the absence of microarray data.

Found at DOI: 10.1371/journal.ppat.0020052.st004 (49 KB DOC).

**Table S5.** Effect of Gene Silencing on *P. falciparum* Infection (Oocyst Numbers)

*Plasmodium falciparum* oocyst loads in midguts of gene knockdowns (KD) and their controls (GFP). The efficiency of gene KD (%) is presented in Table S6. The KD and GFP control mosquitoes in each dataset were fed on the same *P. falciparum* gametocyte culture. The results of equal numbers of midguts from all three experiments in each dataset were pooled. The total midgut numbers (midguts #), mean and standard error of oocyst numbers (Mean  $\pm$  SE), range of oocyst numbers (range),  $n$ -fold difference of the mean oocyst numbers between gene KD and control (GFP) mosquitoes, and the  $p$  value from two independent probability tests (KS and Mann-Whitney test) are presented. Zero oocysts are also included for calculation of mean oocyst numbers. The repressive (–) effects of genes on parasite survival are shown in parentheses, with the asterisks indicating statistical significant at the 95% confidence level. NS indicates not significantly different. For calculation of mean oocyst numbers, midguts with zero oocysts were included.

Found at DOI: 10.1371/journal.ppat.0020052.st005 (58 KB DOC).

**Table S6.** Effect of Gene Silencing on *P. berghei* Infection (Oocyst Numbers)

*P. berghei* oocyst loads in midguts of gene knockdowns (KD) and their controls (GFP). The KD and GFP mosquitoes in each dataset were fed on the same infected mouse. Data represent a pool of at least three independent randomly selected experiments with equal numbers of midguts. The efficiency of gene KD (%) on average, the total midgut numbers (midguts #), mean, and standard error of oocyst numbers



(Mean  $\pm$  SE), range of oocyst numbers (range),  $n$ -fold difference of the mean oocyst numbers between gene KD and control (GFP) mosquitoes, and the  $p$  value from Kolmogorov-Smirnov test and Mann-Whitney test are presented. The repressive (–) effects of genes on parasite survival are shown in parentheses, with asterisks indicating the statistical significance at the 95% confidence level. NS indicates not significantly different. For calculation of mean oocyst numbers, midguts with zero oocysts were excluded.

Found at DOI: 10.1371/journal.ppat.0020052.st006 (89 KB DOC).

**Table S7.** List of Selected ML Proteins for Phylogenetic Analysis

Found at DOI: 10.1371/journal.ppat.0020052.st007 (45 KB DOC).

## Acknowledgments

We thank Drs. Carolina Barillas-Mury, George K. Christophides, Fotis C. Kafatos, Elena A. Levashina, and Liangbiao Zheng for fruitful discussions. We thank Dr. Thomas J. Templeton and Dr. Johannes T. Dessens for providing the *Plasmodium* CTRP disruption mutant strain, the Johns Hopkins Array Core Facility for providing the microarray equipment, and the Johns Hopkins Malaria Research Institute insectary and parasitology core facilities for assistance with mosquito rearing and infections. We thank Dr. Richard E. Thompson at the

Biostatistics Center at the Department of Biostatistics, Johns Hopkins School of Public Health, for advice on data analysis and interpretation. We thank Dr. Deborah McClellan at the Editing Referral Service, William H. Welch Medical Library, Johns Hopkins University School of Medicine.

**Author contributions.** YD conducted *Plasmodium* and bacterial infection assays, RNAi assays, and real-time quantitative PCR assays. RA provided technical assistance with RNAi assays. EM predicted and annotated the *Anopheles gambiae* transcriptome from the available genome sequence as of September 2004. EW performed gene-silencing assays with GNBPB1. ZX performed bacteria infection gene expression assays. GD designed microarray oligonucleotide sequences and performed microarray hybridization assays and was mainly responsible for the experimental design.

**Funding.** This work has been supported by the National Institutes of Health/National Institute of Allergy and Infectious Disease 1R01AI061576-01A1 and 1 R01 AI059492-01A1, the Ellison Medical Foundation, the World Health Organization/TDR, a Johns Hopkins School of Public Health Faculty Innovation Grant, the Johns Hopkins Malaria Research Institute, and a Marjorie Gilbert Award.

**Competing interests.** The authors have declared that no competing interests exist.

## References

- Osta MA, Christophides GK, Vlachou D, Kafatos FC (2004) Innate immunity in the malaria vector *Anopheles gambiae*: Comparative and functional genomics. *J Exp Biol* 207: 2551–2563.
- Osta MA, Christophides GK, Kafatos FC (2004) Effects of mosquito genes on *Plasmodium* development. *Science* 303: 2030–2032.
- Luckhart S, Vodovotz Y, Cui L, Rosenberg R (1998) The mosquito *Anopheles stephensi* limits malaria parasite development with inducible synthesis of nitric oxide. *Proc Natl Acad Sci U S A* 95: 5700–5705.
- Vizioli J, Bulet P, Hoffmann JA, Kafatos FC, Muller HM, et al. (2001) Gambicin: A novel immune responsive antimicrobial peptide from the malaria vector *Anopheles gambiae*. *Proc Natl Acad Sci U S A* 98: 12630–12635.
- Kim W, Koo H, Richman AM, Seeley D, Vizioli J, et al. (2004) Ectopic expression of a cecropin transgene in the human malaria vector mosquito *Anopheles gambiae* (Diptera: Culicidae): Effects on susceptibility to *Plasmodium*. *J Med Entomol* 41: 447–455.
- Vizioli J, Bulet P, Charlet M, Lowenberger C, Blass C, et al. (2000) Cloning and analysis of a cecropin gene from the malaria vector mosquito, *Anopheles gambiae*. *Insect Mol Biol* 9: 75–84.
- Vlachou D, Schlegelmilch T, Christophides GK, Kafatos FC (2005) Functional genomic analysis of midgut epithelial responses in *Anopheles* during *Plasmodium* invasion. *Curr Biol* 15: 1185–1195.
- Meister S, Kanzok SM, Zheng XL, Luna C, Li TR, et al. (2005) Immune signaling pathways regulating bacterial and malaria parasite infection of the mosquito *Anopheles gambiae*. *Proc Natl Acad Sci U S A* 102: 11420–11425.
- Tahar R, Boudin C, Thiery I, Bourgooin C (2002) Immune response of *Anopheles gambiae* to the early sporogonic stages of the human malaria parasite *Plasmodium falciparum*. *EMBO J* 21: 6673–6680.
- Becker K, Tilley L, Vennerstrom JL, Roberts D, Rogerson S, et al. (2004) Oxidative stress in malaria parasite-infected erythrocytes: Host-parasite interactions. *Int J Parasitol* 34: 163–189.
- Lim J, Gowda DC, Krishnegowda G, Luckhart S (2005) Induction of nitric oxide synthase in *Anopheles stephensi* by *Plasmodium falciparum*: Mechanism of signaling and the role of parasite glycosylphosphatidylinositols. *Infect Immun* 73: 2778–2789.
- Han YS, Thompson J, Kafatos FC, Barillas-Mury C (2000) Molecular interactions between *Anopheles stephensi* midgut cells and *Plasmodium berghei*: The time bomb theory of ookinete invasion of mosquitoes. *EMBO J* 19: 6030–6040.
- Sinden RE, Alavi Y, Raine JD (2004) Mosquito-malaria interactions: A reappraisal of the concepts of susceptibility and refractoriness. *Insect Biochem Mol Biol* 34: 625–629.
- Ghosh A, Edwards MJ, Jacobs-Lorena M (2000) The journey of the malaria parasite in the mosquito: Hopes for the new century. *Parasitol Today* 16: 196–201.
- Aguilar R, Dong Y, Warr E, Dimopoulos G (2005) *Anopheles* infection responses: Laboratory models versus field malaria transmission systems. *Acta Trop* 95: 285–291.
- Gupta L, Kumar S, Han YS, Pimenta PF, Barillas-Mury C (2005) Midgut epithelial responses of different mosquito-*Plasmodium* combinations: The actin cone zipper repair mechanism in *Aedes aegypti*. *Proc Natl Acad Sci U S A* 102: 4010–4015.
- Dimopoulos G, Christophides GK, Meister S, Schultz J, White KP, et al. (2002) Genome expression analysis of *Anopheles gambiae*: Responses to injury, bacterial challenge, and malaria infection. *Proc Natl Acad Sci U S A* 99: 8814–8819.
- Christophides GK, Zdobnov E, Barillas-Mury C, Birney E, Blandin S, et al. (2002) Immunity-related genes and gene families in *Anopheles gambiae*. *Science* 298: 159–165.
- Beier JC (1998) Malaria parasite development in mosquitoes. *Annu Rev Entomol* 43: 519–543.
- Yang IV, Chen E, Hasseman JP, Liang W, Frank BC, et al. (2002) Within the fold: Assessing differential expression measures and reproducibility in microarray assays. *Genome Biol* 3: research0062.
- Inohara N, Nunez G (2002) ML—a conserved domain involved in innate immunity and lipid metabolism. *Trends Biochem Sci* 27: 219–221.
- Zdobnov EM, von Mering C, Letunic I, Torrents D, Suyama M, et al. (2002) Comparative genome and proteome analysis of *Anopheles gambiae* and *Drosophila melanogaster*. *Science* 298: 149–159.
- Levashina EA, Moita LF, Blandin S, Vriend G, Lagueux M, et al. (2001) Conserved role of a complement-like protein in phagocytosis revealed by dsRNA knock-out in cultured cells of the mosquito, *Anopheles gambiae*. *Cell* 104: 709–718.
- Dimopoulos G, Richman A, Muller HM, Kafatos FC (1997) Molecular immune responses of the mosquito *Anopheles gambiae* to bacteria and malaria parasites. *Proc Natl Acad Sci U S A* 94: 11508–11513.
- Dziarski R (2004) Peptidoglycan recognition proteins (PGRPs). *Mol Immunol* 40: 877–886.
- Kobe B, Deisenhofer J (1994) The leucine-rich repeat: A versatile binding motif. *Trends Biochem Sci* 19: 415–421.
- Davies G, Henrissat B (1995) Structures and mechanisms of glycosyl hydrolases. *Structure* 3: 853–859.
- Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, et al. (2002) Essential role of MD2 in LPS responsiveness and TLR4 distribution. *Nat Immunol* 3: 667–672.
- Gobert V, Gottar M, Matskevich AA, Rutschmann S, Royet J, et al. (2003) Dual activation of the *Drosophila* toll pathway by two pattern recognition receptors. *Science* 302: 2126–2130.
- Blandin S, Shiao SH, Moita LF, Janse CJ, Waters AP, et al. (2004) Complement-like protein TEPI is a determinant of vectorial capacity in the malaria vector *Anopheles gambiae*. *Cell* 116: 661–670.
- Kumar S, Christophides GK, Cantera R, Charles B, Han YS, et al. (2003) The role of reactive oxygen species on *Plasmodium* melanotic encapsulation in *Anopheles gambiae*. *Proc Natl Acad Sci U S A* 100: 14139–14144.
- Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci U S A* 95: 14863–14868.
- Shi L, Paskewitz SM (2004) Identification and molecular characterization of two immune-responsive chitinase-like proteins from *Anopheles gambiae*. *Insect Mol Biol* 13: 387–398.
- Concha MI, Smith VJ, Castro K, Bastias A, Romero A, et al. (2004) Apolipoproteins A-I and A-II are potentially important effectors of innate immunity in the teleost fish *Cyprinus carpio*. *Eur J Biochem* 271: 2984–2990.
- Whitten MM, Tew IF, Lee BL, Ratcliffe NA (2004) A novel role for an insect apolipoprotein (apolipoprotein III) in beta-1,3-glucan pattern recognition and cellular encapsulation reactions. *J Immunol* 172: 2177–2185.
- Miller SI, Ernst RK, Bader MW (2005) LPS, TLR4 and infectious disease diversity. *Nat Rev Microbiol* 3: 36–46.
- Sinden RE (2004) A proteomic analysis of malaria biology: Integration of old literature and new technologies. *Int J Parasitol* 34: 1441–1450.
- Xu X, Dong Y, Abraham EG, Kocan A, Srinivasan P, et al. (2005) Transcriptome analysis of *Anopheles stephensi*-*Plasmodium berghei* interactions. *Mol Biochem Parasitol* 142: 76–87.

39. Collins FH, Sakai RK, Vernick KD, Paskewitz S, Seeley DC, et al. (1986) Genetic selection of a *Plasmodium*-refractory strain of the malaria vector *Anopheles gambiae*. *Science* 234: 607–610.
40. Vernick KD, Fujioka H, Seeley DC, Tandler B, Aikawa M, et al. (1995) *Plasmodium gallinaceum*: A refractory mechanism of ookinete killing in the mosquito, *Anopheles gambiae*. *Exp Parasitol* 80: 583–595.
41. Blandin S, Moita LF, Kocher T, Wilm M, Kafatos FC, et al. (2002) Reverse genetics in the mosquito *Anopheles gambiae*: Targeted disruption of the Defensin gene. *EMBO Rep* 3: 852–856.
42. Dimopoulos G, Seeley D, Wolf A, Kafatos FC (1998) Malaria infection of the mosquito *Anopheles gambiae* activates immune-responsive genes during critical transition stages of the parasite life cycle. *EMBO J* 17: 6115–6123.
43. Brown MR, Raikhel AS, Lea AO (1985) Ultrastructure of midgut endocrine cells in the adult mosquito, *Aedes aegypti*. *Tissue Cell* 17: 709–721.
44. Luckhart S, Li K, Dunton R, Lewis EE, Crampton AL, et al. (2003) *Anopheles gambiae* immune gene variants associated with natural *Plasmodium* infection. *Mol Biochem Parasitol* 128: 83–86.
45. Morlais I, Poncon N, Simard F, Cohuet A, Fontenille D (2004) Intraspecific nucleotide variation in *Anopheles gambiae*: New insights into the biology of malaria vectors. *Am J Trop Med Hyg* 71: 795–802.
46. Shiff CJ, Minjas JN, Hall T, Hunt RH, Lyimo S, et al. (1995) Malaria infection potential of anopheline mosquitoes sampled by light trapping indoors in coastal Tanzanian villages. *Med Vet Entomol* 9: 256–262.
47. Richman AM, Bulet P, Hetru C, Barillas-Mury C, Hoffmann JA, et al. (1996) Inducible immune factors of the vector mosquito *Anopheles gambiae*: Biochemical purification of a defensin antibacterial peptide and molecular cloning of preprodefensin cDNA. *Insect Mol Biol* 5: 203–210.
48. Lowenberger CA, Kamal S, Chiles J, Paskewitz S, Bulet P, et al. (1999) Mosquito–*Plasmodium* interactions in response to immune activation of the vector. *Exp Parasitol* 91: 59–69.
49. Christophides GK (2005) Transgenic mosquitoes and malaria transmission. *Cell Microbiol* 7: 325–333.
50. Benedict MQ (1997) Care and maintenance of anopheline mosquitoes. In: Crampton JM, Beard CB, Louis C, editors. *The molecular biology of disease vectors: A methods manual*. London: Chapman & Hall. pp. 3–12.
51. Carter R, Ranford-Cartwright L, Alano P (1993) The culture and preparation of gametocytes of *Plasmodium falciparum* for immunochemical, molecular, and mosquito infectivity studies. *Methods Mol Biol* 21: 67–88.
52. Aguilar R, Jedlicka AE, Mintz M, Mahairaki V, Scott AL, et al. (2005) Global gene expression analysis of *Anopheles gambiae* responses to microbial challenge. *Insect Biochem Mol Biol* 35: 709–719.
53. Birney E, Andrews TD, Bevan P, Caccamo M, Chen Y, et al. (2004) An overview of Ensembl. *Genome Res* 14: 925–928.
54. Curwen V, Eyraas E, Andrews TD, Clarke L, Mongin E, et al. (2004) The Ensembl automatic gene annotation system. *Genome Res* 14: 942–950.
55. Stalker J, Gibbins B, Meidl P, Smith J, Spooner W, et al. (2004) The Ensembl web site: Mechanics of a genome browser. *Genome Res* 14: 951–955.
56. Hammond MP, Birney E (2004) Genome information resources—developments at Ensembl. *Trends Genet* 20: 268–272.
57. Kasprzyk A, Keefe D, Smedley D, London D, Spooner W, et al. (2004) EnsMart: A generic system for fast and flexible access to biological data. *Genome Res* 14: 160–169.
58. Chou HH, Hsia AP, Mooney DL, Schnable PS (2004) Picky: Oligo microarray design for large genomes. *Bioinformatics* 20: 2893–2902.
59. Dudoit S, Gentleman RC, Quackenbush J (2003) Open source software for the analysis of microarray data. *Biotechniques* (Suppl): 45–51.
60. Herrero J, Al-Shahrour F, Diaz-Urriarte R, Mateos A, Vaquerizas JM, et al. (2003) GEPAS: A web-based resource for microarray gene expression data analysis. *Nucleic Acids Res* 31: 3461–3467.